Beyfortus
MarketedAn RSV-prevention antibody injection for all newborns and infants, prescribed in Korea since 5 February 2025.
FROM PUBLIC EVENTS · 2026-11-18
Commercial · sales Supplies vaccines and rare-disease treatments in Korea and is widening clinical partnerships with Korean hospitals.
Roles often seen at this stageSales & marketing · Medical & MSL · Regulatory affairs
The Korean arm of global drugmaker Sanofi, supplying vaccines and treatments for immune diseases, rare diseases, diabetes and cancer in Korea.
An RSV-prevention antibody injection for all newborns and infants, prescribed in Korea since 5 February 2025.
A haemophilia B treatment; a May 2026 label change in Korea allows storage at up to 30°C for as long as six months.
A Korean label change allowing room-temperature storage of the haemophilia drug Alprolix took effect.
Signed an agreement with Seoul National University Hospital on AI- and digital-based clinical trial innovation.
Signed an MOU with Deepcardio to improve diagnosis of Fabry disease.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.